neuroinflammation-ad-pathway

neuroinflammation-ad-pathway

Neuroinflammation has emerged as a critical component of Alzheimer's disease (AD) pathogenesis, representing both a consequence of [amyloid-beta](/proteins/amyloid-beta) (Aβ) and [tau](/proteins/tau) pathology and a driver of disease progression. This page synthesizes current understanding of the neuroinflammatory cascade in AD, from microglial activation to chronic neuroinflammation and its downstream effects on neurodegeneration.

Overview

Neuroinflammation in AD is characterized by persistent activation of brain immune cells, particularly [microglia](/cell-types/microglia-neuroinflammation) and [astrocytes](/entities/astrocytes), leading to a chronic inflammatory state that contributes to neuronal dysfunction and death. While acute neuroinflammation serves protective functions, chronic dysregulation becomes deleterious, creating a feed-forward loop with pathological protein aggregates[@heneka2015].

The recognition that neuroinflammation is not merely a secondary phenomenon but an active driver of AD pathogenesis has led to significant research interest in inflammatory pathways as therapeutic targets. Genome-wide association studies (GWAS) have identified multiple immune-related genetic risk factors for AD, including [TREM2](/genes/trem2), [CD33](/genes/cd33), and [PLCG2](/genes/plcg2), underscoring the importance of immune dysfunction in disease etiology[@jansen2019].

Microglial Activation in AD

Morphological and Functional Transformation

neuroinflammation-ad-pathway

Neuroinflammation has emerged as a critical component of Alzheimer's disease (AD) pathogenesis, representing both a consequence of [amyloid-beta](/proteins/amyloid-beta) (Aβ) and [tau](/proteins/tau) pathology and a driver of disease progression. This page synthesizes current understanding of the neuroinflammatory cascade in AD, from microglial activation to chronic neuroinflammation and its downstream effects on neurodegeneration.

Overview

Neuroinflammation in AD is characterized by persistent activation of brain immune cells, particularly [microglia](/cell-types/microglia-neuroinflammation) and [astrocytes](/entities/astrocytes), leading to a chronic inflammatory state that contributes to neuronal dysfunction and death. While acute neuroinflammation serves protective functions, chronic dysregulation becomes deleterious, creating a feed-forward loop with pathological protein aggregates[@heneka2015].

The recognition that neuroinflammation is not merely a secondary phenomenon but an active driver of AD pathogenesis has led to significant research interest in inflammatory pathways as therapeutic targets. Genome-wide association studies (GWAS) have identified multiple immune-related genetic risk factors for AD, including [TREM2](/genes/trem2), [CD33](/genes/cd33), and [PLCG2](/genes/plcg2), underscoring the importance of immune dysfunction in disease etiology[@jansen2019].

Microglial Activation in AD

Morphological and Functional Transformation

Brain-resident microglia are the primary immune cells of the central nervous system. In AD, microglia undergo dramatic morphological and functional changes:

• Resting microglia ( surveillant state): Highly ramified morphology with small cell bodies and long processes
• Activated microglia: Amoeboid morphology with enlarged cell bodies and shortened processes
• Disease-associated microglia (DAM): A specialized subset that clusters around amyloid plaques

TREM2 and Microglial Surveillance

[TREM2](/genes/trem2) (Triggering Receptor Expressed on Myeloid Cells 2) is a critical receptor on microglia that recognizes amyloid plaques and other disease-associated signals. [TREM2](/proteins/trem2) variants, particularly the R47H mutation, significantly increase AD risk:

• TREM2 is expressed on microglia, not [neurons](/entities/neurons)
• R47H mutation reduces ligand binding (Aβ, lipids, apolipoproteins)
• Impaired microglial clustering around plaques
• Reduced plaque compaction and increased diffuse plaque burden
• Loss of protective microglial responses[@wang2015]

Microglial States in AD

Single-cell RNA sequencing has identified multiple microglial states in AD brain:

The Neuroinflammatory Cascade

Aβ-Induced Microglial Activation

Amyloid-beta directly activates microglia through multiple mechanisms:

• TLRs (Toll-like receptors), especially TLR2 and [TLR4](/genes/tlr4)
• [RAGE](/proteins/ager-protein) (Receptor for Advanced Glycation Endproducts)
• CD14 co-receptor

• Aβ triggers NLRP3 inflammasome assembly
• Caspase-1 activation
• IL-1β and IL-18 maturation and release
• Chronic inflammation amplification[@heneka2013]

Cytokine and Chemokine Release

Activated microglia release a array of pro-inflammatory mediators:

| Mediator | Function | AD Relevance |
|----------|----------|---------------|
| IL-1β | Pro-inflammatory cytokine | Elevated in AD brain, drives tau pathology |
| TNF-α | Cytotoxicity, inflammation | Neurotoxic, correlates with cognitive decline |
| IL-6 | Acute phase response | Associated with disease progression |
| CXCL8 (IL-8) | Neutrophil chemoattractant | Recruitment of peripheral immune cells |
| CCL2 (MCP-1) | Monocyte recruitment | Attracts microglia to plaques |

Astrocyte Reactivity

Astrocytes also undergo reactive changes in AD:

• Reactive astrocytes (A1 phenotype) release complement components
• Astrocytic plaques form around amyloid deposits
• Dysregulated glutamate uptake leads to excitotoxicity
• Impaired potassium buffering
• Reduced astrocyte-neuron metabolic coupling[@liddelow2017]

Chronic Neuroinflammation Mechanisms

Complement System Activation

The [complement system](/entities/complement-system) is heavily implicated in AD pathogenesis:

The complement cascade may mediate synaptic loss in AD, with C1q and C3 participating in the tagging and elimination of synapses[@stevens2007].

Glial Limiting Membranes and Barrier Dysfunction

The glia limitans (perivascular and subpial glia limitans) forms a barrier between the brain parenchyma and vascular/ventricular compartments. In AD:

• Dysfunction allows increased peripheral immune cell infiltration
• Breakdown enables toxic blood-borne substances to enter brain
• Contributes to cerebral amyloid angiopathy (CAA)

Blood-Brain Barrier Permeability

[Blood-Brain Barrier](/mechanisms/blood-brain-barrier) dysfunction in AD includes:

• Reduced tight junction protein expression (claudin-5, occludin)
• Increased matrix metalloproteinase (MMP) activity
• Pericyte loss and capillary rarefaction
• Enhanced leukocyte trafficking

Neuroinflammation-Tau Interaction

Bidirectional Relationship

Neuroinflammation and tau pathology interact in a bidirectional manner:

• IL-1β enhances tau phosphorylation via [GSK3β](/genes/gsk3b) and [CDK5](/genes/cdk5)
• TNF-α promotes tau aggregation
• Microglial [exosomes](/entities/exosomes) spread phosphorylated tau

• NFT-bearing neurons release inflammatory signals
• Tau oligomers activate microglia
• Neuronal death releases DAMPs[@maphis2015]

Microglial Exosome Spread

Microglia secrete exosomes containing:

• Hyperphosphorylated tau
• Inflammatory cytokines
• Complement components
• Aβ

Genetic Evidence: Immune Risk Factors

GWAS-Identified AD Risk Genes

Multiple immune-related genes influence AD risk:

| Gene | Variant | Effect | Mechanism |
|------|---------|--------|----------|
| [TREM2](/genes/trem2) | R47H | ~3x risk | Reduced microglial Aβ recognition |
| [CD33](/genes/cd33) | rs3865444 | Protective | Reduced inhibitory signaling |
| [APOE](/genes/apoe) | ε4 | ~4x risk | Impaired Aβ clearance, enhanced inflammation |
| [PLCG2](/genes/plcg2) | P522R | Protective | Enhanced microglial signaling |
| [ABI3](/genes/abi3) | rs28348800 | Risk | Impaired microglial phagocytosis |
| [INPP5D](/genes/inpp5d) | rs35349673 | Risk | Altered microglial signaling |

HLA-DRB5 and Immune Regulation

The HLA-DRB5 region shows complex associations with AD, reflecting the role of MHC class II molecules in antigen presentation and immune regulation[@lambert2013].

Therapeutic Implications

Anti-Inflammatory Approaches

Multiple therapeutic strategies target neuroinflammation:

Challenges

Anti-inflammatory trials in AD have largely failed:

• Late intervention may miss therapeutic window
• Broad immunosuppression may be harmful
• Need for precise targeting of pathological inflammation
• Biomarker-guided patient selection required

Mermaid Pathway Diagram

Cross-Linking to Related Pages

• [TREM2](/genes/trem2)
• [CD33](/genes/cd33)
• [APOE](/genes/apoe)
• [Tau Protein](/proteins/map-tau-protein)
• [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Microglia in Neurodegeneration](/cell-types/microglia-neurodegeneration)

Key Findings

See Also

• [TREM2](/genes/trem2)
• [CD33](/genes/cd33)
• [PLCG2](/genes/plcg2)
• [APOE](/genes/apoe)
• [ABI3](/genes/abi3)
• [INPP5D](/genes/inpp5d)
• [Neurofibrillary Tangles](/mechanisms/neurofibrillary-tangles)
• [Tau Protein](/proteins/map-tau-protein)
• [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway)
• [Alzheimer's Disease](/diseases/alzheimers-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)